ANI Pharmaceuticals, Inc. filings document financial results, operating updates, governance matters, and material events for its Rare Disease, Generics, and Brands businesses. Form 8-K reports furnish earnings releases, preliminary results, guidance updates, Regulation FD investor presentations, and corporate changes such as independent auditor matters.
ANI proxy filings cover shareholder voting items, board governance, executive compensation, equity awards, and related governance disclosures. The filing record also provides formal context for product and business risks tied to biopharmaceutical development, FDA-regulated generic launches, branded products, commercialization, manufacturing, and capital actions.
ANI Pharmaceuticals (ANIP) announced a recommended public cash offer for all outstanding shares of Egetis Therapeutics, its convertible loan and warrants, and entered into a 364-day senior bridge facility for borrowings of up to $676 million. The offer is SEK 11.25 per share, SEK 65,750,817 for the EUR 3 million principal amount of the convertible loan, and SEK 6.99 per warrant. Egetis’ board unanimously recommended acceptance; shareholders representing approximately 42.2% of outstanding shares gave undertakings to accept, subject to conditions.
Completion is conditional on tenders for at least 90% of Egetis shares on a fully diluted basis and required regulatory clearances; ANI may waive conditions. The acceptance period is expected to run from on or around November 20 through on or around December 18, 2026. Settlement is expected to begin on or around December 29, 2026, if the offer is declared unconditional by around December 21, 2026. Financing combines cash on hand and debt from JPMorgan Chase Bank; the facility may also refinance ANI’s existing term loans and certain Egetis debt. Initially unsecured, the facility would, if funded, be guaranteed by certain subsidiaries and secured by substantially all assets of ANI and certain subsidiaries, subject to customary exceptions.
ANI Pharmaceuticals (ANIP) reported net revenue of $290.8 million and net income of $35.1 million for the three months ended September 30, 2026, compared with $227.8 million and $26.6 million, respectively, a year earlier. Diluted earnings per share were $1.51, versus $1.13. For the nine months ended September 30, revenue was $794.3 million and net income was $89.4 million, compared with $636.3 million and $50.8 million in 2025.
Cortrophin Gel generated $138.7 million of third-quarter revenue, compared with $101.9 million. Generics and Other generated $108.4 million, compared with $98.7 million. Under its Harmony agreement, ANI recognized $9.5 million in pitolisant-product royalties and $2.0 million in development milestone revenue during the quarter.
Net cash provided by operating activities was $198.8 million for the first nine months, compared with $154.9 million in 2025. Cash and cash equivalents were $420.8 million as of September 30, 2026, versus $285.6 million as of December 31, 2025. During the quarter, ANI repurchased 102,492 common shares for approximately $7.5 million under a program authorizing repurchases of up to $100.0 million.
ANI Pharmaceuticals, Inc. reported third-quarter 2026 revenue of $290.8 million, up 27.6% year over year, GAAP net income available to common shareholders of $35.1 million ($1.51 diluted EPS), and adjusted non-GAAP EBITDA of $83.3 million, up 39.8%. Rare Disease revenue was $160.9 million, including Cortrophin Gel revenue of $138.7 million; Generics and Other revenue was $108.4 million. Cortrophin gout patient cases doubled quarter over quarter, though specialty-pharmacy capacity constraints slowed revenue conversion.
Revised 2026 guidance is $1,085–$1,125 million in total revenue, $480–$500 million in Cortrophin Gel revenue (previously $520–$540 million), $290–$300 million in adjusted EBITDA and $9.37–$9.71 in adjusted diluted EPS. ANI made a recommended public offer for Egetis shares, convertible debt and warrants; the share price is SEK 11.25. The offer value is approximately SEK 5.6 billion (about $560 million), including outstanding incentive programs. Closing requires acceptances for at least 90% of Egetis shares and regulatory approvals. Financing includes cash and up to $300 million of committed bridge debt. Through November 2, ANI repurchased 275,635 shares for approximately $20.0 million.
ANI Pharmaceuticals (ANIP) SVP & CFO Stephen P. Carey reported selling 2,850 shares of Common Stock on October 29, 2026, at a weighted-average price of $72.87 per share. The sales were made under a Rule 10b5-1 trading plan adopted on March 6, 2026. The reported price reflects multiple trades ranging from $72.18 to $73.29; Carey directly held 166,143 shares after the sale.
ANI Pharmaceuticals, Inc. officer Stephen P. Carey filed a notice of a proposed sale of 8,550 common shares, with an aggregate market value of $613,120.50 and an approximate sale date of October 29, 2026. Morgan Stanley Smith Barney LLC is named as broker. Carey’s shares were acquired through vesting of restricted stock awards from March 31, 2021 through April 10, 2021. The past-three-months table lists 10b5-1 sales of 2,850 shares each on August 31 and September 29, 2026.
ANI Pharmaceuticals Inc. President and CEO Nikhil Lalwani sold 5,400 shares of common stock on October 15, 2026, at a weighted average price of $71.89 per share. The multiple trades ranged from $71.08 to $72.56 per share and were made under a Rule 10b5-1 trading plan adopted May 26, 2026. Lalwani directly held 333,689 shares after the sale.
ANI Pharmaceuticals, Inc. common stock is the subject of Nikhil Lalwani’s notice to sell 5,400 shares, with an aggregate market value of $378,864.00 and an approximate sale date of October 15, 2026. Morgan Stanley Smith Barney LLC is listed as broker. The notice identifies the shares as acquired upon vesting of restricted stock units from February 28 through March 7, 2026.
It also lists two sales under the “10b5-1 Sales” heading: 5,400 shares on September 15, 2026, for $383,400.00 and 5,400 shares on August 25, 2026, for $401,216.22.
ANI Pharmaceuticals (ANIP) Senior Vice President, General Counsel & SEC. Meredith Cook sold 500 shares of common stock directly on October 13, 2026, at $73.59 per share. She held 73,424 shares directly after the sale. The transaction was made under a Rule 10b5-1 trading plan Meredith Cook adopted on September 15, 2025.
ANI Pharmaceuticals Inc. (ANIP) reported that its SVP & CFO, Stephen P. Carey, sold 2,850 shares of common stock on September 29, 2026, at a weighted average price of $73.00 per share. The sale was made under a Rule 10b5-1 trading plan adopted on March 6, 2026. Carey directly held 168,993 shares after the sale.
ANI PHARMACEUTICALS INC (ANIP) reports that President and CEO Nikhil Lalwani sold 5,400 shares of common stock on September 15, 2026 at $71.00 per share, for about $383,400 in total proceeds. After this transaction, he directly holds 339,089 shares. The sale was effected under a Rule 10b5-1 trading plan adopted on May 26, 2026.